Reference

• data sets represented by a given reference, references may appear on more than one occasion depending on the extent of data extraction i.e. treated and non-treated populations from the same article are presented separately if possible

Mutation type

• reported as per Table II. All refer to the amino acid sequence number assigned according to reference sequence gi: 29725608 Amino acid alterations are reported as single letter abbreviations

Confirmed somatic

• confirmed to be somatic by analysis of normal cells; Yes or No (in most instances not all samples have been proven somatic)

≥ 2 mutations

• patients with ≥2 reported somatic mutation are noted, these include patients with T790M, BUT do not include patients with silent polymorphisms or germ line single nucleotide polymorphisms (SNPs). Patients with T790M mutations have typically developed the mutation following TKI based therapy; therefore the majority of these patients have already been included in the tables (both mutation and response). Readers are advised to investigate these cases with caution. All other cases of dual (or multiple mutations) occurring in one individual have been recorded in both the mutation and response tables as independent events according to each individual mutation. Therefore, there are additional patient numbers associated throughout the data set and the associated tables. Considering that they represent an approximated <1.7% of the total population readers are advised to interpret the presented tables and data sets bearing this in mind

Gender

• ♂ = Male; ♀ = Female

Ethnicity

• based upon ethnicity of the biological specimens used in the study. More than one ethnicity may occur per reference

Pathology
(histological type)

• adenocarcinoma = adenocarcinomas combined with any histology with BAC component (bronchioalviolar component, e.g. BACs, AWFB, BWFI), adenosquamous are included with other; Other = all other histologies

Smoking status

• Smoker = current, previous with no limit on pack year; Non-smoker = assumed never smokers

TKI

• tyrosine kinase inhibitor (TKI); E = Erlotinib (Tarceva); G = Gefitinib (Iressa). As yet no data has been assigned to combination versus single agent therapy, nor treatment period, or disease stage; C = chemotherapy

Response criteria

• reported as RECIST (R), WHO, SWOG

Author confirmation
and date

• date at which corresponding author confirmed the data set

Sample Source

• PET = paraffin embedded tissue; FF = fresh frozen tissue; Other = as indicated

Analyte

• DNA=mutational analysis conducted on extracted DNA; RNA = mutational analysis conducted on tissue extracted RNA

Exons examined

• exons screened per study (individual mutation through to entire gene)

Technique

• Seq = Bi-directional Sequencing; RFLP = restriction fragment length polymorphism; TaqMan = TaqMan probes (typically 13 different mutations, unless otherwise stated); Surveyor = Combined Taqman like format with enhancement of mutant allele; SSCP = single strand conformational polymorphism; MEP = mutant enriched PCR

^

• not reported, or not directly extractable from the data source

Treatment response

• CR = complete response; PR = partial response; SD = stabilization of disease; PD = progressive disease; NE = non-evaluable

Treatment status

• status at the time of TKI initiation: P = previously treated with chemotherapy, determined to be ineligible to receive standard chemotherapy; N = chemotherapy naïve

No Patients - WT

• number of samples with wild type EGFR sequence (WT)

No Patients - Mutant

• number of samples with a somatic mutation in EGFR (Mut)